Pharma BD Deal Intelligence
AstraZeneca's $2.7B acquisition of ZS Pharma bought a novel hyperkalemia treatment, giving AstraZeneca a foothold in a chronic kidney disease and heart failure adjacent market. The strategic case rested on cardio-renal synergies with AstraZeneca's existing cardiovascular portfolio, though the treatment's commercial ramp has been slower than the deal price implied.
AstraZeneca acquired ZS Pharma for $2.7B for hyperkalemia treatment.
AstraZeneca completes acquisition of ZS Pharma on December 17 2015 with 86.6 percent of outstanding shares validly tendered in the offer.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquired ZS Pharma for $2.7B for hyperkalemia treatment.
Lokelma (sodium zirconium cyclosilicate) is positioned as a RAASi-enabling adjunct in HF/CKD, allowing continuation of guideline-directed medical therapy by managing hyperkalemia; it competes with one direct MOA class and faces pressure from therapies that reduce hyperkalemia risk upstream. Non-absorbed potassium binders (direct competitors): Veltassa (patiromer, CSL Vifor) is the first-in-class polymer potassium binder, FDA approved 2015, with DIAMOND Phase 3 data demonstrating enablement of spironolactone/ACEi/ARB dose maintenance in HFrEF; Kayexalate (sodium polystyrene sulfonate, generic) remains the legacy low-cost option despite GI safety concerns. Nonsteroidal MRAs (upstream hyperkalemia-sparing disruptor): Kerendia (finerenone, Bayer) FDA-approved for CKD/T2D with FIGARO-DKD and FIDELIO-DKD CV outcomes data; lower hyperkalemia rates than spironolactone threaten binder demand when MRA class shifts. SGLT2 inhibitors: Farxiga (dapagliflozin, AstraZeneca, roughly $6B global) and Jardiance (empagliflozin, Boehringer/Lilly, roughly $7B global) are now foundational in HFrEF/HFpEF/CKD (DAPA-HF, EMPEROR-Reduced, EMPA-KIDNEY) and modestly lower serum potassium, reducing binder pull-through. ARNi: Entresto (sacubitril/valsartan, Novartis) dominates HFrEF. Commercial threat for Lokelma is dual-pronged: patiromer head-to-head in the potassium binder class (similar efficacy, formulary contests) and upstream finerenone/SGLT2 adoption reducing persistent hyperkalemia incidence.
Lokelma (sodium zirconium cyclosilicate) competes in a two-innovator plus legacy-generic hyperkalemia market. Non-absorbed inorganic cation-trapping compounds: Lokelma is FDA-approved (2018) for adult hyperkalemia excluding acute life-threatening settings, with rapid onset (~1 hour) and sodium load as a noted disadvantage; AstraZeneca reported Lokelma 2023 product sales of roughly $400M with double-digit growth. Non-absorbed polymer potassium binders: Veltassa (patiromer, CSL Vifor) is the principal direct competitor, FDA approved 2015, calcium-exchanging polymer with slower onset (~7 hours) but preferred in sodium-restricted HF populations; PEARL-HF, AMBER, and DIAMOND data support RAASi enablement. Legacy cation-exchange resins: Kayexalate (sodium polystyrene sulfonate) and calcium polystyrene sulfonate generics remain in formularies at low cost despite FDA boxed warning for GI ischemia/necrosis and limited evidence base. Loop diuretics (furosemide, bumetanide, torsemide generics) and IV insulin/glucose plus albuterol remain acute hospital standard but are not chronic alternatives. Pipeline: no late-stage novel hyperkalemia agents are expected to disrupt through 2027 per AstraZeneca pipeline disclosures. Commercial threat is primarily payer-driven step-therapy preferences between Lokelma and patiromer, with upstream SGLT2 and nonsteroidal MRA (Kerendia, finerenone, Bayer) adoption reducing chronic hyperkalemia prevalence over time.
AstraZeneca completed $2.7B acquisition of ZS Pharma, gaining Lokelma (sodium zirconium cyclosilicate) for hyperkalemia in CKD patients.
FDA approved Lokelma for hyperkalemia, enabling continued RAASi use in heart failure and CKD patients as a potassium-lowering agent.
Lokelma is approved and growing but not yet blockbuster. $2.7B was aggressive for supportive care drug. Revenue below peak expectations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / ZS Pharma Inc. (this deal) | 2015 | $2.7B | 72 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2015 deals · AstraZeneca PLC deals · Cardiovascular deals